Exhibit 99.1
NicoWater logo
QT 5 ANNOUNCES NATIONAL LAUNCH AND ROLLOUT OF NICOWATER(TM)
--------
MULTI-MILLION DOLLAR DEVELOPMENT PROGRAM CULMINATES IN BREAKTHROUGH
HOMEOPATHIC PRODUCT
Westlake Village, CA (PR Newswire) May 28, 2003 QT 5, Inc. (OTC BB QTFV),
manufacturer and marketers of NICOWater(TM), the breakthrough Homeopathic
nicotinum (nicotine) product designed to relieve symptoms of tobacco cravings,
announced today the national launch and roll-out NICOWater(TM). NICOWater(TM),
the result of a multi-million dollar investment program over a year in
development, is now being rolled out nationally.
"This is a very exciting threshold moment in QT 5's history as this
revolutionary Homeopathic product -- over which the management, employees and
our partners have labored intensively for a year - now comes to market," stated
Steven Reder, QT 5's President. "Our breakthrough product -- specifically
targeting the extraordinarily attractive $200 billon market for tobacco and
tobacco products -- has been engineered to satisfy smokers' cravings when they
can't smoke or shouldn't smoke, an increasingly common dilemma for smokers in
today's restrictive public and private environments." Mr. Reder went on to say,
"QT 5 is populated by a dynamic management team which has defined a compelling
opportunity to capitalize on a market populated by over 25% of all Americans.
Our burgeoning company, which sustained significant losses in the development
and manufacturing of this state-of-the-art Homeopathic product, will now begin
to reap the rewards of its labor by addressing the needs of these millions of
American smokers."
ABOUT QT 5, INC.
QT 5, Inc. is a Delaware corporation formed in April 1999 as a manufacturer,
distributor and marketer of Bio-Med testing and Homeopathic products. QT 5, Inc.
is continuing its clinical research and development of future products for
lifestyle enhancements. QT 5, Inc. is headquartered in Westlake Village,
California. For more information please visit: www.qt5inc.com. NICOWater(TM)is
sold under the FDA's Compliance Policy Guide Conditions Under Which Homeopathic
Drugs May Be Marketed. For additional information on QT 5, Inc. contact
Bernadette Cusack, Vice President - Investor Relations, Trilogy Capital
Partners, bernadette@trilogy-capital.com.
20
CAUTIONARY STATEMENT
THIS RELEASE CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE RISKS AND
UNCERTAINTIES, SUCH AS STATEMENTS ABOUT OUR PLANS, OBJECTIVES, EXPECTATIONS,
ASSUMPTIONS OR FUTURE EVENTS. THESE STATEMENTS INVOLVE ESTIMATES, ASSUMPTIONS,
KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND PERFORMANCES, OR ACHIEVEMENTS
EXPRESSED OR IMPLIED BY THE FORWARD-LOOKING STATEMENT. ACTUAL FUTURE RESULTS AND
TRENDS MAY DIFFER MATERIALLY FROM THOSE MADE IN OR SUGGESTED BY ANY
FORWARD-LOOKING STATEMENTS DUE TO A VARIETY OF FACTORS, INCLUDING, FOR EXAMPLE,
OUR ABILITY TO COMPETE WITH OTHER PRODUCTS IN OUR SPACE; THE RISK OF UNFAVORABLE
FEDERAL REGULATION; AND THE FACT THAT OUR STATUS AS A DEVELOPMENT STATE COMPANY
MAKES OUR FUTURE UNCLEAR. CONSEQUENTLY YOU SHOULD NOT PLACE UNDUE RELIANCE ON
THESE FORWARD-LOOKING STATEMENTS. WE DISCUSS MANY OF THESE AND OTHER RISKS AND
UNCERTAINTIES IN GREATER DETAIL UNDER THE SECTION ENTITLED, "RISK FACTORS THAT
MAY AFFECT FUTURE RESULTS" IN ITEM 1 OF THE COMPANY'S CURRENT REPORT ON FORM 8-K
AS FILED WITH SEC ON JANUARY 24, 2003 (THE "MERGER FORM 8-K").
CONTACT
Bernadette Cusack, Vice President
Trilogy Capital Partners, Inc.
800.330.6540
bernadette@trilogy-capital.com
- ------------------------------